COMPASS Pathways plc
COMP360
treatment-resistant depression (TRD)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews COMP360 for treatment-resistant depression (TRD) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“White House Executive Order on psychedelics treatments directs the Drug Enforcement Administration (DEA) to initiate and complete review of psychedelic treatment that has successfully completed Phase 3 trials so that rescheduling may procee”